Literature DB >> 16456761

[Perspectives of cannabinoids in gastroenterology].

M Storr1, B Yüce, B Göke.   

Abstract

In early cultures, extracts of the plant Cannabis sativa were medically used for the treatment of gastrointestinal symptoms like nausea, vomiting, diarrhoea and abdominal pain. In the United States cannabis extracts were frequently used as drugs, e. g., for the treatment of diarrhoea, until around 1920. The possibility of cannabis abuse resulted in a worldwide prohibition and thus the temporary ending of the medical use of cannabinoids. The characterisation of an endogenous cannabinoid system consisting of receptors, endogenous agonists, antagonists and degrading enzymes opens the door for a comeback of cannabinoids in medicine. The clinically proven effects in the treatment of pain, cachexia in conjunction with HIV, or malignant disease and treatment of nausea and vomiting in conjunction with chemotherapy now result in the prescription of cannabinoids as valuable medication. This review will discuss the value of cannabinoids in the treatment of nausea and vomiting, i. e., the indications for which cannabinoids are presently used in gastroenterology. Additionally, this review will discuss potential indications within gastroenterology, where results from basic research or individual observations suggest that a future use of cannabinoids in gastroenterology seems possible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456761     DOI: 10.1055/s-2005-858931

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  3 in total

1.  The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease.

Authors:  Martin Storr; Dominik Emmerdinger; Julia Diegelmann; Simone Pfennig; Thomas Ochsenkühn; Burkhard Göke; Peter Lohse; Stephan Brand
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

2.  Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis.

Authors:  Martin A Storr; Catherine M Keenan; Hong Zhang; Kamala D Patel; Alexandros Makriyannis; Keith A Sharkey
Journal:  Inflamm Bowel Dis       Date:  2009-11       Impact factor: 5.325

3.  Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.

Authors:  Martin A Storr; Catherine M Keenan; Dominik Emmerdinger; Hong Zhang; Birol Yüce; Andrei Sibaev; Federico Massa; Nancy E Buckley; Beat Lutz; Burkhard Göke; Stephan Brand; Kamala D Patel; Keith A Sharkey
Journal:  J Mol Med (Berl)       Date:  2008-05-21       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.